Singapore, The Next Asia-Pacific Biomedical Hub

The Asia-Pacific (APAC) region is the third largest biopharmaceutical market in the world, and has seen a shift from predominantly producing generics to developing innovative technologies. In the last 20 years, a rapid growth has been observed in the APAC region life science industry, due to increased R&D activity, a flow of mergers and acquisitions, a large population and market demand from several aging societies. The market is expected to be growing at a CAGR of 10.05% and reaching USD 64.96 billion by 2027.

This has led to the development of several biotech hubs in the region that are leading the way in biopharma innovation and sustainability. Supported by these developments, the APAC biotech market is estimated to expand at a rapid compound annual growth rate of 16.8 percent up to 2028.

Among these biomedical hubs, Singapore is a leading biomedical sciences hub at the heart of Asia, and is the choice location for companies to develop and produce new products that better meet Asia's healthcare needs. With its proximity to the rest of Asia, pro-business environment, extensive government support, infrastructure, talent and innovation ecosystem, Singapore is a leading hub for best-in-class manufacturing plants, where innovative products are launched and produced; professionals meet and network.

For instance, big pharma companies such as GlaxoSmithKline, Pfizer, Novartis and Sanofi, have been drawn to Singapore and set up its manufacturing facilities and it is worth noticing that four of the top 10 drugs by global revenue are manufactured in Singapore. Besides, more than 25 R&D centers have also been established by multinational medical technology companies and there are more than 350 biotech companies in Singapore, from startups to small-medium enterprises.

In this e-Book, the Biomedical hub in Singapore, Biologics companies outline and Singapore's attractiveness as the ideal biologics hub in the APAC region will be introduced.

Download the e-Book HERE

‍